{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Status:
Investigational
Source:
NCT03302416: Early Phase 1 Interventional Completed Healthy
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:clofutriben [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03255096: Phase 1 Interventional Completed Diffuse Large B-cell Lymphoma
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01989598: Phase 2 Interventional Completed Recurrent Plasma Cell Myeloma
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Uprosertib is an oral potent Akt inhibitor which acts equally on Akt1, Akt2 and Akt3. The drug is under clinical development in combination with trametinib for the treatment of different cancers, including melanoma, myeloma, breast, endometrial, cervical cancer, etc.
Status:
Investigational
Source:
NCT04327024: Phase 2 Interventional Completed Heart Failure With Preserved Ejection Fraction (HFpEF)
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. Verinurad specifically inhibits URAT1 with a potency of 25 nM. High affinity inhibition of uric acid transport requires URAT1 residues Cys-32, Ser-35, Phe-365 and Ile-481. Unlike other available uricosuric agents, the requirement for Cys-32 is unique to verinurad. Verinurad doses as low as 2.5 mg produce significant sUA lowering in humans, and this greater reduction in sUA may lead to improved outcomes and medical benefits for patients with gout. Verinurad in monotherapy studies has been associated with increased urinary uric acid concentrations and low rates of serum creatinine (sCr) elevation. Verinurad combined with febuxostat decreased sUA dose-dependently while maintaining uric acid excretion similar to baseline. All dose combinations of verinurad and febuxostat were generally well tolerated.
Status:
Investigational
Source:
INN:flurdihydroergotamine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03040973: Phase 2 Interventional Recruiting Advanced Solid Tumors Which Are cMET-dependent
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Novartis Oncology (previously Novartis) is developing nazartinib (formerly EGF 816), a third generation mutant-selective tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), for the treatment of solid malignancies, with a focus on non-small cell lung cancer. Nazartinib is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min−1 on EGFR(L858R/790M) mutant, respectively. Upon oral administration, nazartinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. EGF816 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.
Status:
Investigational
Source:
NCT01701089: Phase 1 Interventional Completed Healthy Volunteer, Alzheimer's Disease
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
L-DEPRENYL-D2 C-11 is a selective irreversible inhibitor of monoamine oxidase B (Mao-B) which labels functionally active enzyme. It is used as a positron emission tomography radioligand for measurement of the Mao-B activity in vivo brain.
Status:
Investigational
Source:
NCT00506077: Phase 2 Interventional Completed Paranoid Schizophrenia
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
MK-0249 is a potent H3 receptor inverse agonist patented by Abbott Laboratories for treatment of cognitive deficits. MK-0249 demonstrates promising results in preclinical models of cognitive disorders. MK0249 has been used in trials studying the treatment of Hypopnea Syndrome, Alzheimer's Disease, Paranoid Schizophrenia ets. Unfortunately, MK-0249 failed to demonstrate efficacy in schizophrenia, mild-to-moderate Alzheimer's Disease, attention-deficit/hyperactivity disorder, and future development has been discontinued.
Status:
Investigational
Source:
Hum Exp Toxicol. May 1996;15(5):369-75.: Not Applicable Human clinical trial Completed N/A
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
